Under RNTCP, what is the recommended duration of directly observed therapy (DOT) for a new smear-positive pulmonary TB patient in the intensive phase?

Explanation

## RNTCP Intensive Phase Duration **Key Point:** The intensive phase of treatment for new smear-positive TB patients is **2 months** of directly observed therapy (DOT), during which the patient receives the first-line anti-TB drugs (HRZE). ### Standard RNTCP Regimen | Phase | Duration | Drugs | Frequency | Observation | | --- | --- | --- | --- | --- | | Intensive | 2 months | HRZE | Daily | DOT mandatory | | Continuation | 4 months | HR | Daily | DOT for first 2 weeks, then self-administered | **High-Yield:** The total treatment duration is 6 months (2 months intensive + 4 months continuation), not the intensive phase alone. This is a common source of confusion in exams. **Clinical Pearl:** After the 2-month intensive phase, if the patient remains smear-positive, an extended intensive phase of 1 additional month may be considered before moving to continuation phase. **Mnemonic:** **2-4-6 Rule** — 2 months intensive (HRZE), 4 months continuation (HR), 6 months total duration.